Delcath Systems, Inc. (Nasdaq: DCTH) announced that the first patient has been dosed in its global Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE